Evofem Biosciences to Present at H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) announced its presentation at the H.C. Wainwright Global Life Sciences Conference on February 23, 2021. CEO Saundra Pelletier will discuss the commercialization of Phexxi®, a non-hormonal birth control method. The presentation will be available for on-demand listening starting March 9, 2021, at 7:00 a.m. ET on their website. Additionally, on Valentine's Day, Evofem launched a DTC campaign called 'Get Phexxi' to enhance awareness of its product.

Phexxi® is the first and only hormone-free prescription vaginal gel in the U.S. for pregnancy prevention.

SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will present at the upcoming H.C. Wainwright Global Life Sciences Conference. Evofem's CEO, Saundra Pelletier, will provide an update on the commercialization of its non-hormonal, use-it-only-when-you-need-it birth control method, Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel.

The presentation will be available for on-demand listening  beginning Tuesday, March 9, 2021, at 7:00 a.m. ET on the Investors section of the Company's website at www.evofem.com, under the Events and Presentations tab; click here for direct access.

On Valentine's Day, the Company launched "Get Phexxi", a national direct-to-consumer (DTC) campaign aimed at broadening Phexxi's awareness. Click here to view the "Get Phexxi" commercial on demand.

About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first commercial product, Phexxi®, is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company's lead product candidate, EVO100, is being evaluated for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women in the ongoing Phase 3 clinical trial, 'EVOGUARD'. For more information, please visit www.evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775

Media Contact
Ellen Thomas
Evofem Biosciences, Inc.
ethomas@evofem.com
Mobile: (718) 490-3248

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-hc-wainwright-global-life-sciences-conference-301232996.html

SOURCE Evofem Biosciences, Inc.

FAQ

What is Evofem Biosciences presenting at the H.C. Wainwright Conference?

Evofem Biosciences will present the commercialization of its non-hormonal birth control method, Phexxi®, led by CEO Saundra Pelletier.

When will Evofem's presentation be available for listening?

The presentation will be available for on-demand listening beginning March 9, 2021, at 7:00 a.m. ET.

What is Phexxi® and its significance?

Phexxi® is a non-hormonal, prescription vaginal gel approved in the U.S. for pregnancy prevention, marking a significant advancement in women's reproductive health.

What campaign did Evofem launch for Phexxi®?

On Valentine's Day, Evofem launched the 'Get Phexxi' DTC campaign to increase awareness about its product.

What is the stock symbol for Evofem Biosciences?

The stock symbol for Evofem Biosciences is EVFM.